Traws Pharma Puts Phase 2 Influenza Trial on Hold After UK Regulator Feedback

Traws Pharma shares fell after delaying its Phase 2 human influenza challenge study due to negative feedback from the UK’s MHRA. The company is now advancing backup flu antiviral candidates.